CINOVA: a phase II study of CPC634 (nanoparticulate docetaxel) in patients with platinum resistant recurrent ovarian cancer.
Ingrid A BoereIgnace VergoteRob HanssenMathilde JalvingChristine GennigensPetronella OttevangerYes J van de WouwCristianne J F RijckenRon H J MathijssenJonathan A LedermannPublished in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2023)
Treatment with CPC634 was feasible, but without apparent clinical activity in patients with recurrent platinum-resistant ovarian cancer. Side effects were mainly gastrointestinal in 24 (96%) patients, including nausea, vomiting, and decreased appetite, fatigue, anemia, and dyspnea.
Keyphrases
- phase ii study
- end stage renal disease
- chronic kidney disease
- ejection fraction
- newly diagnosed
- locally advanced
- prognostic factors
- chemotherapy induced
- randomized controlled trial
- magnetic resonance imaging
- magnetic resonance
- squamous cell carcinoma
- physical activity
- rectal cancer
- palliative care
- radiation therapy
- patient reported